Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.
about
Current therapies for lowering lipoprotein (a)Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trialsOxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study).Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trialOxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis).High prevalence of raised lipoprotein(a) in patients with refractory anginaAcute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemiaAntisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansMCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma.Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis.Genetic associations with valvular calcification and aortic stenosisDeterminants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).New aspects of gene-silencing for the treatment of cardiovascular diseasesLipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease riskAntisense technology: an emerging platform for cardiovascular disease therapeutics.Development of Antisense Drugs for Dyslipidemia.Lipoprotein(a) for risk assessment in patients with established coronary artery disease.Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).Critical review of non-statin treatments for dyslipoproteinemia.The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.Lipoprotein(a) as a therapeutic target in cardiovascular disease.Molecular biology of calcific aortic valve disease: towards new pharmacological therapies.The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory anginaNovel metabolic biomarkers of cardiovascular disease.Targeting lipoprotein (a): an evolving therapeutic landscape.New and emerging biomarkers in cardiovascular disease.Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.Development of lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis.Hyperlipoproteinaemia(a) - apheresis and emerging therapies.Lipoprotein(a)-clinical aspects and future challengesLipoprotein(a): A Lipoprotein Whose Time Has Come.New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis.The role of lipoprotein (a) in chronic kidney disease.miR-23b-3p and miR-125b-5p downregulate apo(a) expression by targeting Ets1 in HepG2 cells.Dramatic fate of a young coronary heart disease patient rescued with specific lipoprotein(a) apheresis.Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold?
P2860
Q26830297-6CD72FE9-EEEA-4068-87C3-D9D606E4BAAEQ28077742-25AD44EC-4F76-4264-9E1F-45D394FD05F0Q33857831-140BE3DB-938C-452F-85BC-8F7E7F20BCB1Q34224722-28E56036-4BBC-4E73-A7FD-FC5BCEF78F1FQ35276226-864ECB2D-93A3-4488-94CA-5A7A50528FD6Q35592510-13D6F705-126B-4B7B-931A-8F92CF4ED66DQ36148940-5EC0E650-4B68-4239-9EF4-73A9A9750502Q36187468-0057F714-9B88-4896-8216-16FA8B467C7EQ36520326-D3981B1D-B619-4CDD-AF4F-35E266FD4381Q36617508-FB84FF73-D533-42FC-B31D-5711A829A864Q36920584-D8A323E0-3A03-4785-908E-F56A4054DC65Q36930213-03894C29-429C-431A-B1CE-592822C5D229Q37154922-E9AD9CA8-67F1-4AE0-9ACF-222239B4ECEDQ37163064-9715250E-5167-4310-86D0-8AC5AD831AD7Q37277425-082143B4-22A5-486C-8B05-52DDB4B10ACCQ37334501-F1BB3748-97FA-4469-B15D-538958D226FAQ37337608-9E74A559-B541-4F26-9202-5E222634A9C0Q37387192-A76F0E54-8FC5-41AB-A4D6-F574334A1FD8Q37622149-48EA89FA-0F17-41C4-8838-E367D8660CCDQ37623853-908E7A2F-6AF9-4A81-8E6C-03F3D509DF2EQ38186099-8242F7A2-44F0-4898-81E7-500BC096CC64Q38201960-4045B480-B036-418D-A2B0-55269BF70C1EQ38213476-6A653095-51A9-4ABA-924F-9F4236952B81Q38214362-3B8FB7B9-0267-4616-A3AA-271605E38EAAQ38233052-0DB6F985-F061-4E03-89A9-DED41E178966Q38245327-880BDD32-C0C8-4A2B-86E1-F11C66CDE694Q38367355-7C208E3F-4D51-4E02-8534-5825C2CB0450Q38586900-354DB006-0503-4FBF-9A26-63A744D28A9BQ38701405-5A8B494C-575D-4580-A708-CA19BFE729DDQ38918257-66261601-D8D9-4741-B542-B38BD712B04BQ38968510-0B86987F-127A-4D0B-B56C-4308E1767831Q39033744-31F85CD3-63C5-4091-8774-B072A58A097FQ39308941-C2B190D0-6D7B-4F11-B204-5D8CFB6665CCQ44760819-CB3E4441-2F9D-4925-9C0E-24375B48092FQ49598174-40351879-9EC4-4C44-9495-B1020EF9412AQ50075849-4A7AE6E2-9BAC-49DF-AD6C-080115B5912CQ51058242-C3657630-F66C-418D-9F89-29EB42E5581FQ51614577-7597E487-503F-4749-9C4A-7E09E7205C58
P2860
Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Antisense oligonucleotide lowe ...... rotein (a) in transgenic mice.
@en
Antisense oligonucleotide lowers plasma levels of apolipoprotein
@nl
type
label
Antisense oligonucleotide lowe ...... rotein (a) in transgenic mice.
@en
Antisense oligonucleotide lowers plasma levels of apolipoprotein
@nl
prefLabel
Antisense oligonucleotide lowe ...... rotein (a) in transgenic mice.
@en
Antisense oligonucleotide lowers plasma levels of apolipoprotein
@nl
P2093
P50
P1476
Antisense oligonucleotide lowe ...... rotein (a) in transgenic mice.
@en
P2093
Adam E Mullick
Adam Taleb
Elizabeth R Miller
Esther Merki
Mark Graham
Peter Willeit
Richard Lee
Rosanne M Crooke
Xiaohong Yang
P304
P356
10.1016/J.JACC.2010.10.052
P407
P577
2011-04-01T00:00:00Z